Clinical Chemistry AACC Online Job Center
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 54: 1166-1175, 2008. First published May 16, 2008; 10.1373/clinchem.2007.087148
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow HTML Page - index.htslp
Right arrow All Versions of this Article:
clinchem.2007.087148v1
54/7/1166    most recent
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Google Scholar
Right arrow Articles by Kyselova, Z.
Right arrow Articles by Novotny, M. V.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kyselova, Z.
Right arrow Articles by Novotny, M. V.
Related Collections
Right arrow Proteomics and Protein Markers
(Clinical Chemistry. 2008;54:1166-1175.)
© 2008 American Association for Clinical Chemistry, Inc.

Proteomics and Protein Markers

Breast Cancer Diagnosis and Prognosis through Quantitative Measurements of Serum Glycan Profiles

Zuzana Kyselova1, Yehia Mechref1,a, Pilsoo Kang1, John A. Goetz1, Lacey E. Dobrolecki2, George W. Sledge2,4, Lauren Schnaper3, Robert J. Hickey2,4, Linda H. Malkas2,4 and Milos V. Novotny1,4,a

1 National Center for Glycomics and Glycoproteomics, Department of Chemistry, Indiana University, Bloomington, IN; 2 Department of Medicine, Indiana University School of Medicine, Indianapolis, IN; 3 Breast Cancer Center, Greater Baltimore Medical Center, Baltimore, MD; 4 Indiana University Cancer Center, Indianapolis, IN.

aAddress correspondence to these authors at: Department of Chemistry, Indiana University, 800 E. Kirkwood Ave., Bloomington, IN 47405. Fax 812-855-8300; e-mail novotny{at}indiana.edu, ymechref{at}indiana.edu.

Background: Glycosylated proteins play important roles in cell-to-cell interactions, immunosurveillance, and a variety of receptor-mediated and specific protein functions through a highly complex repertoire of glycan structures. Aberrant glycosylation has been implicated in cancer for many years.

Methods: We performed specific MALDI mass spectrometry (MS)-based glycomic profile analyses of permethylated glycans in sera from breast cancer patients (12, stage I; 11, stage II; 9, stage III; and 50, stage IV) along with sera from 27 disease-free women. The serum glycoproteins were enzymatically deglycosylated, and the released glycans were purified and quantitatively permethylated before their MALDI-MS analyses. We applied various statistical analysis tools, including ANOVA and principal component analysis, to evaluate the MS profiles.

Results: Two statistical procedures implicated several sialylated and fucosylated N-glycan structures as highly probable biomarkers. Quantitative changes according to a cancer stage resulted when we categorized the glycans according to molecular size, number of oligomer branches, and abundance of sugar residues. Increases in sialylation and fucosylation of glycan structures appeared to be indicative of cancer progression. Different statistical evaluations confirmed independently that changes in the relative intensities of 8 N-glycans are characteristic of breast cancer (P < 0.001), whereas other glycan structures might contribute additionally to distinctions in the statistically recognizable patterns (different stages).

Conclusions: MS-based N-glycomic profiling of serum-derived constituents appears promising as a highly sensitive and informative approach for staging the progression of cancer.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2008 by the American Association for Clinical Chemistry.